Boston Partners
WX

Boston Partners’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Boston Partners’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-80,000
Closed -$3.46M – 787
2015
Q3 		$3.46M Hold
80,000
– – 0.01% 541
2015
Q2 		$3.38M Sell
80,000
-40,000
-33% -$1.69M ﹤0.01% 565
2015
Q1 		$4.65M Hold
120,000
– – 0.01% 524
2014
Q4 		$4.04M Buy
120,000
+3,070
+3% +$108K 0.01% 559
2014
Q3 		$4.09M Sell
116,930
-28,631
-20% -$981K 0.01% 546
2014
Q2 		$4.78M Sell
145,561
-66,214
-31% -$2.27M 0.01% 526
2014
Q1 		$7.81M Buy
211,775
+19,150
+10% +$703K 0.01% 440
2013
Q4 		$7.39M Hold
192,625
– – 0.02% 443
2013
Q3 		$5.28M Sell
192,625
-40,835
-17% -$968K 0.01% 484
2013
Q2 		$4.9M Buy
+233,460
New +$4.56M 0.01% 472

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Boston Partners's WX Position: Q4 2015 in Review

Boston Partners sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 80,000 shares — an estimated $3.46M sold.

Boston Partners first reported a position in WX in Q2 2013 and held it in 10 quarters. The position peaked at $7.81M in Q1 2014. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • Boston Partners reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • Boston Partners sold 80,000 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $3.46M.
  • Boston Partners first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 10 quarters.
  • Boston Partners's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $7.81M in Q1 2014.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Boston Partners's 13F filing for Q4 2015, filed 8 Feb 2016.